In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-β1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 59, Issue 9, 2004, Pages 927-932

  Profita, M ^a   Gagliardo, R ^a   Di Giorgi, R ^a   Bruno, A ^a   Riccobono, L ^a   Bonanno, A ^a   Bousquet, J ^b   Vignola, A M ^a,c  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b INSERM   (France)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Airway remodelling; Asthma; Flunisolide; Metalloproteinases; Sputum cells

Indexed keywords

FIBRONECTIN; FLUNISOLIDE; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANALYTIC METHOD; APOPTOSIS; ARTICLE; ASTHMA; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NICK END LABELING; PRIORITY JOURNAL; SPUTUM ANALYSIS; SPUTUM CULTURE;

ADULT; APOPTOSIS; ASTHMA; FIBRONECTINS; FLUOCINOLONE ACETONIDE; HUMANS; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SPUTUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 4344612477     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00516.x     Document Type: Article

References (38)

1. VIGNOLA AM, KIPS J, BOUSQUET J. Tissue remodeling as a feature of persistent asthma. J Allergy Clin Immunol 2000;105(6 Pt 1):1041-1053.
2. MOSHER D, SOTTILE J, WU C, MCDONALD J. Assembly of extracellular matrix. Curr Opin Cell Biol 1992;4:810-818.
3. MURPHY G, DOCHERTY AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992;7: 120-125.
4. MATRISIAN LM. The matrix-degrading metalloproteinases. Bioessays 1992;14:455-463.
5. CAMPBELL EJ, CURY JD, SHAPIRO SD, GOLDBERG GI, WELGUS HG. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J Immunol 1991;146:1286-1293.
6. KOVACS E, DIPIETRO L. Fibrogenic cytokines and connective tissue production. Faseb J 1994;8:854-861.
7. KHALIL N, O'Connor RN, UNRUH HW, WARREN PW, FLANDERS KC, KEMP A et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991;5:155-162.
8. CORRIN B, BUTCHER D, MCANULTY BJ, DUBOIS RM, BLACK CM, LAURENT GJ et al. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24:145-150.
9. ELOVIC A, WONG DT, WELLER PF, MATOSSIAN K, GALLI SJ. Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol 1994;93:864-869.
10. BRACH MA, SOTT C, KIEHNTOPF M, HERRMANN F. Expression of the transforming growth factor-alpha gene by human eosinophils is regulated by interleukin-3, interleukin-5, and granulocyte-macrophage colony-stimulating factor. Eur J Immunol 1994;24:646-650.
11. KADIN M, BUTMARC J, ELOVIC A, WONG D. Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease. Am J Pathol 1993;142:11-16.
12. OHNO I, LEA RG, FLANDERS KC, CLARK. DA, BANWATT D. DOLOVICH J et al. Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J Clin Invest 1992;89:1662-1668.
13. BORDER W, NOBLE N. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
14. MAGNAN A, FRACHON I, RAIN B, PEUCHMAUR M, MONTI G, LENOT B et al. Transforming growth factor β in normal human lung: preferential location in bronchial epithelial cells. Thorax 1994;49:789-792.
15. WAKEFIELD LM, SMITH DM, MASUI T, HARRIS CC, SPORN MB. Distribution and modulation of the cellular receptor for transforming growth factor-beta. J Cell Biol 1987;105:965-975.
16. WHO/NHLBI Workshop Report. National Institutes of Health NH, Lung and Blood Institute. Global Strategy for asthma management and prevention. Publication Number 1995;95:3659.
17. VIGNOLA AM, CHANEZ P, CAMPBELL AM, SOUQUES F, LEBEL B, ENANDER I et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998; 157:403-409.
18. HARGREAVE FE, POPOV T, KIDNEY J, DOLOVICH J. Sputum measurements to assess airway inflammation in asthma. Allergy 1993;48(Suppl. 17):81-83.
19. STAFANGER G. In vitro effect of beclomethasone dipropionate and flunisolide on the mobility of human nasal cilia. Allergy 1987;42:507-511.
20. VIGNOLA AM, RICCOBONO L, MIRABELLA A, PROFITA M, CHANEZ P, BELLIA V et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Resp Crit Care Med 1998;158: 1945-1950.
21. DANIELPOUR D. Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor beta 1. J Immunol Methods 1993;158:17-25.
22. VIGNOLA AM, CHANEZ P, CHIAPPARA G, SIENA L, MERENDINO A, REINA C et al. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol 1999;103: 563-573.
23. BOUSQUET J, YSSEL H, VIGNOLA AM. Is allergic asthma associated with delayed fetal maturation or the persistence of conserved fetal genes? Allergy 2000;55:1194-1197.
24. JEFFERY PK, GODFREY RW, ADELROTH E, NELSON F, ROGERS A, JOHANSSON SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992;145(4 Pt 1):890-899.
25. OLIVIERI D, CHETTA A, DEL-DONNO M, BERTORELLI G, CASALINI A, PESCI A et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997;155:1864-1871.
26. SONT JK, WILLEMS LN, BEL EH, VAN KRIEKEN JH, VANDENBROUCKE JP, STERK PJ. Clinical control and histopathologic outcome of asthma when using airway hyper-responsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159(4 Pt 1): 1043-1051.
27. BEL EH, TIMMERS MC, DIJKMAN JH, STAHL EG, STERK PJ. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol 1990;85:1067-1075.
28. CHEUNG D, TIMMERS MC, ZWINDERMAN AH, BEL EH, DIJKMAN JH, STERK PJ. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-1203.
29. OVERBEEK SE, RIJNBEEK PR, VONS C, MULDER PG, HOOGSTEDEN HC, BOGAARD JM. Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics. Eur Respir J 1996;9:2256-2262.
30. VANACKER NJ, PALMANS E, KIPS JC, PAUWELS RA. The effect of fluticasone on established allergen induced structural airway changes in a rat model. Am J Respir Crit Care Med 1999;159:A113.
31. VANACKER NJ, PALMANS E, KIPS JC, PAUWELS RA. The effect of pretreatment with fluticasone on allergen induced airway changes in a rat model. Am J Respir Crit Care Med 1999;159:A115.
32. VIGNOLA A, CHANEZ P, CHIAPPARA G, MERENDINO A, ZINNANTI E, BOUSQUET J et al. Release of transforming growth factor-β and fibronectin by alveolar macrophages in airway diseases. Clin Exp Immunol 1996;106:114-119.
33. CHU HW, TRUDEAU JB, BALZAR S, WENZEL SE. Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 2000;106:1115-1123.
34. SHAPIRO SD, CAMPBELL EJ, SENIOR RM, WELGUS HG. Proteinases secreted by human mononuclear phagocytes. J Rheumatol Suppl 1991;27:95-98.
35. MAUTINO G, HENRIQUET C, JAFFUEL D, BOUSQUET J, CAPONY F. Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. Am J Respir Crit Care Med 1999;160:324-330.
36. ATSUTA J, FUJISAWA T, IGUCHI K, TERADA A, KAMIYA H, SAKUMA S. Inhibitory effect of transforming growth factor beta on cytokine-enhanced eosinophil survival and degranulation. Int Arch Allergy Immunol 1995;108(Suppl. 1): 31-35.
37. ALAM R. Transforming growth factorβ abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 1994;179:1041-1045.
38. NOMURA A, UCHIDA A, SAKAMOTO Y, ISHII Y, MASUYAMA K, MORISHIMA Y et al. Increases in collagen type I synthesis in asthma: the role of eosinophils and transforming growth factor-β. Clin Exp Allergy 2002;32:860-865.